| Drug ID: | Drug11 |
|---|---|
| Drug Name: | Berberine |
| CID: | 2353 |
| DrugBank ID: | DB04115 |
| Modality: | Small Molecule |
| Groups: | experimental |
| US Approved: | NO |
| Other Approved: | NO |
| Identifier: | NCT02962245 |
| Molecular Formula: | C20H18NO4+ |
| Molecular Weight: | 336.4 g/mol |
| Isomeric SMILES: | COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC |
| Synonyms: | berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; Benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium, 5,6-dihydro-9,10-dimethoxy- |
| Phase 0: | 2 |
| Phase 1: | 4 |
| Phase 2: | 15 |
| Phase 3: | 15 |
| Phase 4: | 21 |
| Description: | An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt90 | 2353 | Berberine | 7124 | TNF | Rattus norvegicus (Norway rat) | 25600690 | Berberine inhibits the reaction [mercuric chloride results in increased expression of TNF protein] |
| dt91 | 2353 | Berberine | 7150 | TOP1 | Homo sapiens (human) | 23747414 | Berberine results in decreased activity of TOP1 protein |
| dt92 | 2353 | Berberine | 7153 | TOP2A | Homo sapiens (human) | 23747414 | TOP2A protein affects the susceptibility to berberine|top2a protein affects the reaction [berberine results in increased expression of H2AX protein modified form] |
| dt93 | 2353 | Berberine | 7157 | TP53 | Homo sapiens (human) | 26712469 | Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein|[berberine co-treated with niacinamide] results in increased expression of and results in increased acetylation of TP53 protein |
| dt94 | 2353 | Berberine | 7157 | TP53 | Homo sapiens (human) | 20656010 | Berberine results in increased expression of TP53 mrna|berberine results in increased expression of TP53 protein |
| dt95 | 2353 | Berberine | 7186 | TRAF2 | Mus musculus (house mouse) | 30240693 | Berberine inhibits the reaction [[lipopolysaccharide, escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]|berberine inhibits the reaction [[lipopolysaccharide, escherichia coli O111 B4 co-treated with TNF |
| dt96 | 2353 | Berberine | 6737 | TRIM21 | Homo sapiens (human) | 36822301 | Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein] |
| dt97 | 2353 | Berberine | 100131187 | TSTD1 | Homo sapiens (human) | 27311644 | Berberine results in increased expression of TSTD1 mRNA |
| dt98 | 2353 | Berberine | 7319 | UBE2A | Homo sapiens (human) | 27311644 | Berberine results in decreased expression of UBE2A mRNA |
| dt99 | 2353 | Berberine | 7320 | UBE2B | Homo sapiens (human) | 27311644 | Berberine results in decreased expression of UBE2B mRNA |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02962245 | Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis | PHASE4 | WITHDRAWN | Xijing Hospital of Digestive Diseases | Ulcerative Colitis | DRUG: berberine|DRUG: regular treatment | Details |
| ChiCTR2400083224 | A clinical trial to evaluate the relationship between nitric oxide content in type 3 natural lymphocytes and severity of enteritis and response to drug intervention in patients with inflammatory bowel disease | Not Available | Not Recruiting | Peking University Third Hospital | Inflammatory Bowel Disease | Trial group:Berberine hydrochloride tablets mesa… | Details |
| NCT02365480 | Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission | PHASE1 | COMPLETED | National Cancer Institute (NCI) | Ulcerative Colitis | DRUG: Berberine Chloride|OTHER: Laboratory Biomar… | Details |
| NCT04985968 | The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis | PHASE3 | TERMINATED | InDex Pharmaceuticals | Ulcerative Colitis | DRUG: Cobitolimod 250 mg|DRUG: Cobitolimod 500 mg… | Details |
| NCT06681181 | A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants | PHASE1 | RECRUITING | GlaxoSmithKline | Colitis, Ulcerative | DRUG: GSK4528287|DRUG: Placebo | Details |
| NCT05992142 | ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA | PHASE4 | COMPLETED | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | Ulcerative Colitis | DRUG: 5-ASA | Details |
| NCT00787202 | A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis. | PHASE2 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: CP- 690 550|DRUG: CP- 690 550|DRUG: CP- 690… | Details |
| NCT06321887 | EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD | PHASE3 | RECRUITING | Liverpool University Hospitals NHS Foundation Trust | Inflammatory Bowel Disease|Iron Deficiency Anemia | DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… | Details |
| NCT00207688 | A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients | None | COMPLETED | Janssen Research & Development, LLC | Ulcerative Colitis | DRUG: Infliximab 5 mg/kg|DRUG: Infliximab 10 mg/k… | Details |
| NCT04677179 | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) | PHASE2 | TERMINATED | Nektar Therapeutics | Colitis, Ulcerative | DRUG: LY3471851|DRUG: Placebo | Details |
| NCT02958865 | Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis | PHASE2 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… | Details |
| NCT03943550 | Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) | PHASE1 | TERMINATED | Hoffmann-La Roche | Ulcerative Colitis | DRUG: RO7049665|DRUG: Placebo | Details |
| NCT02840721 | Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. | PHASE2 | COMPLETED | Telavant, Inc. | Colitis, Ulcerative | DRUG: PF-06480605 | Details |
| NCT04133194 | Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis | PHASE4 | RECRUITING | Flemming Bendtsen | Ulcerative Colitis | DRUG: Mesalazine|DRUG: Mesalazine | Details |
| NCT01465763 | A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis | PHASE3 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: tofacitinib|DRUG: Placebo | Details |
| NCT06636656 | A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis | PHASE2 | RECRUITING | Boehringer Ingelheim | Ulcerative Colitis | DRUG: BI 3032950 intravenous (Part A)|DRUG: BI 30… | Details |
| NCT04996797 | A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) | PHASE2 | ACTIVE_NOT_RECRUITING | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Ulcerative Colitis | DRUG: Tulisokibart|DEVICE: Companion Diagnostic (… | Details |
| NCT01458951 | A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis | PHASE3 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: tofacitinib|DRUG: Placebo | Details |
| NCT04499495 | Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea | None | COMPLETED | Ferring Pharmaceuticals | Ulcerative Colitis | OTHER: PENTASA (mesalamine/ 5-Aminosalicylic acid… | Details |
| NCT01959282 | A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis | PHASE2 | COMPLETED | Janssen Research & Development, LLC | Colitis, Ulcerative | DRUG: Placebo|DRUG: JNJ-54781532 25 mg once daily… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
An oral pH-activated "nano-bomb" carrier combined with berberine by regulating …
PMID: 35037010
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease that features colonic epithelial barrier dysfunction and gut dysbiosis. Pr…
Berberine inhibits dendritic cells differentiation in DSS-induced colitis by pr…
PMID: 34749293
Year: 2021
Relationship Type:
Treatment
Score: 9.5
BACKGROUNDS: Berberine (BBR), a compound long used in traditional Chinese medicine, has been reported to have therapeutic effects in treating ulcerat…
Therapeutic Effects of Berberine Hydrochloride on Stress-Induced Diarrhea-Predo…
PMID: 34594213
Year: 2021
Relationship Type:
Treatment
Score: 9.5
The etiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complicated and closely related to neurotransmission in the gastrointestinal…
Dihydroberberine, an isoquinoline alkaloid, exhibits protective effect against …
PMID: 34253428
Year: 2021
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: As a chronic inflammatory disease, ulcerative colitis (UC) is relevant to a rising risk of colorectal cancer. Dihydroberberine (DHBB), a …
[Research progress of effect of berberine in treatment of ulcerative colitis ba…
PMID: 33645048
Year: 2021
Relationship Type:
Treatment
Score: 9.5
Berberine is the main extract of Coptis chinensis, and its anti-inflammatory, antioxidant, antibacterial and immunomodulatory effects have been confi…
Micro- and Nanoencapsulated Hybrid Delivery System (MNEHDS): A Novel Approach f…
PMID: 33629860
Year: 2021
Relationship Type:
Treatment
Score: 9.5
Berberine (BBR) is currently explored in the oral treatment of many disorders, especially in those involving inflammatory processes. Nanotechnology-b…
To assess the effective and safety of berberine hydrochloride in ulcerative col…
PMID: 33285751
Year: 2020
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: Ulcerative colitis (UC) is an inflammatory bowel disease characterized by a relapsing and remitting course, and the curative medical ther…
Design, synthesis and evaluation of a baicalin and berberine hybrid compound as…
PMID: 33069077
Year: 2020
Relationship Type:
Treatment
Score: 9.5
Structural modification of active natural compoundswhichwereoriginated fromTraditional Chinese Medicine (TCM) have showedgreat advantagesin thedevelo…
Berberine-Loaded Nanostructured Lipid Carriers Enhance the Treatment of Ulcerat…
PMID: 32581538
Year: 2020
Relationship Type:
Treatment
Score: 9.5
PURPOSE: Berberine (BBR), a major ingredient extracted from Coptis chinensis, is a natural drug with limited oral bioavailability. We developed nanos…
Berberine Administration in Treatment of Colitis: A Review
PMID: 32564751
Year: 2020
Relationship Type:
Treatment
Score: 9.5
Berberine (Brb) is one of the well-known naturally occurring compounds exclusively found in Berberis vulgaris and other members of this family, such …
Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modu…
PMID: 32432470
Year: 2020
Relationship Type:
Treatment
Score: 9.5
The natural alkaloid berberine is being studied as a drug candidate for the treatment of ulcerative colitis (UC). Fingolimod is an immunomodulator ap…
Intervention of oncostatin M-driven mucosal inflammation by berberine exerts th…
PMID: 32332711
Year: 2020
Relationship Type:
Treatment
Score: 9.5
Ulcerative colitis (UC) is a chronic and etiologically refractory inflammatory gut disorder. Although berberine, an isoquinoline alkaloid, has been r…
Berberine ameliorates colonic damage accompanied with the modulation of dysfunc…
PMID: 31867696
Year: 2020
Relationship Type:
Treatment
Score: 9.5
Intestinal flora imbalance is one of the potential pathogenesis of inflammatory bowel diseases, and the study aims to discover the effect of berberin…
A Phase I Trial of Berberine in Chinese with Ulcerative Colitis
PMID: 31619442
Year: 2020
Relationship Type:
Treatment
Score: 9.5
The Chinese natural product, berberine, has biological properties that support its potential efficacy as a colon cancer prevention agent. Its longsta…
iTRAQ-based pharmacoproteomics reveals potential targets of berberine, a promis…
PMID: 30771347
Year: 2019
Relationship Type:
Treatment
Score: 9.5
Previous studies by us and others have indicated that berberine is a promising therapy for ulcerative colitis (UC). However, the mechanisms of UC and…
Protective effects of berberine hydrochloride on DSS-induced ulcerative colitis…
PMID: 30743078
Year: 2019
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: Berberine hydrochloride is one the effective compound among Rhizoma Coptidis, Cortex Phellodendri, and other plants. There are several cl…
Demethyleneberberine alleviates inflammatory bowel disease in mice through regu…
PMID: 27900412
Year: 2017
Relationship Type:
Mechanism
Score: 9.3
OBJECTIVE: The activation of NF-kappaB signaling and unbalance of T-helper (Th) cells have been reported to play a key role in the pathogenesis of co…
Improvement of anti-inflammatory and anti-angiogenic activity of berberine by n…
PMID: 24176841
Year: 2014
Relationship Type:
Treatment
Score: 9.3
Berberine, an isoquinoline alkaloid, has wide biological and pharmacological actions. Despite the promising pharmacological effects and safety of ber…
Versatile methods for synthesizing organic acid salts of quaternary berberine-t…
PMID: 27097666
Year: 2016
Relationship Type:
Association
Score: 9.3
Two versatile methods to synthesize kinds of organic acid salts of quaternary berberine-type alkaloids were investigated in order to determine which …
Comparative Study of Berberis vulgaris Fruit Extract and Berberine Chloride Eff…
PMID: 24363687
Year: 2011
Relationship Type:
Treatment
Score: 9.1
Antioxidant and immunomodulatory effects of anthocyanins are abundant in berberry fruits suggesting that they may have beneficial effects on inflamma…